MAPT and Alzheimer disease: Studies in western populations have shown the good diagnostic performance of CSF biomarkers, including Aβ42, phosphorylated tau 181 (P-tau181), and total tau (T-tau), with 85–90% specificity and sensitivity in patients with Alzheimer’s dementia [15, 16].